3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
D. Cella, M. Michaelson, A. Bushmakin, J. Cappelleri, C. Charbonneau, S. Kim, Jim Z. Li, R. Motzer
{"title":"3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)","authors":"D. Cella, M. Michaelson, A. Bushmakin, J. Cappelleri, C. Charbonneau, S. Kim, Jim Z. Li, R. Motzer","doi":"10.1016/S1359-6349(09)70601-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":207270,"journal":{"name":"European Journal of Cancer Supplements","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/S1359-6349(09)70601-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
